When is genomic tumour profiling recommended for bowel cancer?

A sample from the tumour is examined for genetic or molecular features. The result can help identify whether a targeted medicine, immunotherapy approach, or clinical option is biologically relevant. It does not replace the pathology report, scans, or the oncologist’s assessment.

Profiling may be discussed after diagnosis, when the cancer has returned, or when the current treatment is no longer controlling it. The sample may come from surgery or a biopsy; sometimes a new sample is needed if the earlier tissue is insufficient or the tumour has changed.

Ask whether tumour tissue is available and which result would change your treatment plan. Your team may review the cancer’s location, stage, previous medicines, general health, and the quality of the sample before recommending testing.

A profiling report can show an actionable finding, an alteration with no established treatment, or no useful change. Your oncologist will explain what applies to your situation and whether the result supports an approved treatment or another discussion.

Contact your cancer team promptly for new severe abdominal pain, repeated vomiting, a swollen abdomen, inability to pass stool or gas, heavy rectal bleeding, or fever during treatment. These symptoms need assessment regardless of whether profiling has been arranged.

Which tumour features are you testing for, and how could each result affect my options? Is my existing tissue suitable? When should I expect an explanation of the report? Would testing be useful now or at a later treatment decision?